Latest news with #Lane
Chicago Tribune
4 hours ago
- Business
- Chicago Tribune
Purdue Pharma's $7B opioid settlement plan could get votes from victims and cities
OxyContin maker Purdue Pharma 's $7 billion-plus plan to settle thousands of lawsuits over the toll of opioids will go before a judge Friday, potentially setting up votes on whether to accept it for local governments, people who became addicted to the drug and other groups. This month, 49 states announced they have signed on to the the proposal. Only Oklahoma, which has a separate settlement with the company, is not involved. U.S. Bankruptcy Court Judge Sean Lane could decide as soon as Friday whether to advance the nationwide settlement, which was hammered out in negotiations between the company, groups that have sued and representatives of members of the Sackler family who own the company. If Lane moves the plan forward as it's been presented, government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families and others would have until Sept. 30 to vote on whether to accept the deal. The settlement is a way to avoid trials with claims from states alone that total more than $2 trillion in damages. If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the years after OxyContin hit the market in 1996. The other settlements together are worth about $50 billion, and most of the money is to be used to combat the crisis. In the early 2000s, most opioid deaths were linked to prescription drugs, including OxyContin. Since then, heroin and then illicitly produced fentanyl became the biggest killers. In some years, the class of drugs was linked to more than 80,000 deaths, but that number dropped sharply last year. Last year, the U.S. Supreme Court rejected a version of Purdue's proposed settlement. The court found it was improper to protect members of the Sackler family from lawsuits over opioids, even though they themselves were not filing for bankruptcy protection. In the new version, groups that don't opt in to the settlement would still have the right to sue members of the wealthy family whose name once adorned museum galleries around the world and programs at several prestigious U.S. universities. Under the plan, the Sackler family members would give up ownership of Purdue. They resigned from the company's board and stopped receiving distributions from its funds before the company's initial bankruptcy filing in 2019. The remaining entity would get a new name and its profits would be dedicated to battling the epidemic. Most of the money would go to state and local governments to address the nation's addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims. That makes it different from the other major settlements. The payments would not begin until after a hearing, likely in November, during which Judge Lane would be asked to approve the entire plan if enough of the affected parties agree.
4 hours ago
- Business
Purdue Pharma's $7B opioid settlement plan could get votes from victims and cities
OxyContin maker Purdue Pharma 's $7 billion-plus plan to settle thousands of lawsuits over the toll of opioids will go before a judge Friday, potentially setting up votes on whether to accept it for local governments, people who became addicted to the drug and other groups. This month, 49 states announced they have signed on to the the proposal. Only Oklahoma, which has a separate settlement with the company, is not involved. U.S. Bankruptcy Court Judge Sean Lane could decide as soon as Friday whether to advance the nationwide settlement, which was hammered out in negotiations between the company, groups that have sued and representatives of members of the Sackler family who own the company. If Lane moves the plan forward as it's been presented, government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families and others would have until Sept. 30 to vote on whether to accept the deal. The settlement is a way to avoid trials with claims from states alone that total more than $2 trillion in damages. If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the years after OxyContin hit the market in 1996. The other settlements together are worth about $50 billion, and most of the money is to be used to combat the crisis. In the early 2000s, most opioid deaths were linked to prescription drugs, including OxyContin. Since then, heroin and then illicitly produced fentanyl became the biggest killers. In some years, the class of drugs was linked to more than 80,000 deaths, but that number dropped sharply last year. Last year, the U.S. Supreme Court rejected a version of Purdue's proposed settlement. The court found it was improper to protect members of the Sackler family from lawsuits over opioids, even though they themselves were not filing for bankruptcy protection. In the new version, groups that don't opt in to the settlement would still have the right to sue members of the wealthy family whose name once adorned museum galleries around the world and programs at several prestigious U.S. universities. Under the plan, the Sackler family members would give up ownership of Purdue. They resigned from the company's board and stopped receiving distributions from its funds before the company's initial bankruptcy filing in 2019. The remaining entity would get a new name and its profits would be dedicated to battling the epidemic. Most of the money would go to state and local governments to address the nation's addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims. That makes it different from the other major settlements. The payments would not begin until after a hearing, likely in November, during which Judge Lane would be asked to approve the entire plan if enough of the affected parties agree.
San Francisco Chronicle
5 hours ago
- Business
- San Francisco Chronicle
Purdue Pharma's $7B opioid settlement plan could get votes from victims and cities
OxyContin maker Purdue Pharma 's $7 billion-plus plan to settle thousands of lawsuits over the toll of opioids will go before a judge Friday, potentially setting up votes on whether to accept it for local governments, people who became addicted to the drug and other groups. This month, 49 states announced they have signed on to the the proposal. Only Oklahoma, which has a separate settlement with the company, is not involved. U.S. Bankruptcy Court Judge Sean Lane could decide as soon as Friday whether to advance the nationwide settlement, which was hammered out in negotiations between the company, groups that have sued and representatives of members of the Sackler family who own the company. If Lane moves the plan forward as it's been presented, government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families and others would have until Sept. 30 to vote on whether to accept the deal. The settlement is a way to avoid trials with claims from states alone that total more than $2 trillion in damages. If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the years after OxyContin hit the market in 1996. The other settlements together are worth about $50 billion, and most of the money is to be used to combat the crisis. In the early 2000s, most opioid deaths were linked to prescription drugs, including OxyContin. Since then, heroin and then illicitly produced fentanyl became the biggest killers. In some years, the class of drugs was linked to more than 80,000 deaths, but that number dropped sharply last year. Last year, the U.S. Supreme Court rejected a version of Purdue's proposed settlement. The court found it was improper to protect members of the Sackler family from lawsuits over opioids, even though they themselves were not filing for bankruptcy protection. In the new version, groups that don't opt in to the settlement would still have the right to sue members of the wealthy family whose name once adorned museum galleries around the world and programs at several prestigious U.S. universities. Under the plan, the Sackler family members would give up ownership of Purdue. They resigned from the company's board and stopped receiving distributions from its funds before the company's initial bankruptcy filing in 2019. The remaining entity would get a new name and its profits would be dedicated to battling the epidemic. Most of the money would go to state and local governments to address the nation's addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims. That makes it different from the other major settlements. The payments would not begin until after a hearing, likely in November, during which Judge Lane would be asked to approve the entire plan if enough of the affected parties agree.
USA Today
a day ago
- Entertainment
- USA Today
Eagles legend Lane Johnson earns the ultimate compliment from an offensive line expert
Eagles legend Lane Johnson earns the ultimate compliment from an offensive line expert Lane Johnson's greatness has again been put into legendary perspective. Often, Philadelphia Eagles fans and the media members shy away from certain phrases. 'Sure thing' is, no doubt, one of them. How can anyone ever be sure of anything, right? Players may not be ready for the bright lights. Unexpected injuries may occur that derail a career. Guys that we may not expect much from can excel. Still, that being said, though no one admitted it at the time, Lane Johnson kind of felt like a sure thing. He was drafted by Howie Roseman, but Lane was one of the few silver linings from Chip Kelly's era as head coach. He was taken during the first round of the 2013 NFL Draft with the fourth overall pick. Lane was drafted to do what he has done for more than a dozen seasons. Philly asked him to help anchor the offensive line. There were hiccups along the way, but he has more than given the Birds the proper return on their investment. Recently, he was given an elite compliment by one of the most trusted voices when it comes to elite NFL trench play. Lane Johnson's greatness is recognized with the most elite compliment possible They say, when you're good at something, never do it for free. Okay, it was actually the late, great Heath Ledger who said that as The Joker in The Dark Knight movie. You get the idea, though. Sometimes, wisdom can be found in the utterings of a cartoon character. Brandon Thorn has been featured on Bleacher Report, Establish the Run, and at the OL Masterminds Summit. He votes on the Joe Moore Award every season, an honor given to college football's top offensive lineman. He's also the creator of the Trench Warfare newsletter, where he breaks down the intricacies of elite line play. Recently, he offered his opinion on Lane Johnson's brilliance. It's hard to imagine 65 receiving a more elite compliment. Well, he's right. Who's going to argue with that logic? Like a fine wine, Lane Johnson has gotten better with age. The latter stages of his legendary run far exceed what he did early... And, he was damn good early. 6 Pro Bowls... Two First-Team All-Pro nods... Three Second-Team All-Pro nods... And, the most recent Second-Team mention felt like a snub. He should have been voted back to the First Team. Lane is a two-time Super Bowl champion, one of two who are walking the planet. Each season only adds to his Hall-of-Fame resume. NFL Network insider Tom Pelissero reported recently that Lane hopes to play beyond the 2025-26 NFL season, and why wouldn't he? His play is still elite. Is he the greatest right tackle of all time? Here's a vote cast in his favor because, from here, it appears the only thing someone can do is equal his brilliance. He has made it impossible to be better.
Business Wire
2 days ago
- Business
- Business Wire
Health and Welfare Expert Tammy Lane Joins Alliant Insurance Services
IRVINE, Calif.--(BUSINESS WIRE)--Tammy Lane has joined Alliant Insurance Services as Senior Vice President within its Employee Benefits Group. Based in Florida, Lane has more than two decades of experience in the health and welfare benefits space, working with clients nationwide to develop and implement advanced benefits strategies aligned with business goals and evolving workforce needs. 'Tammy brings exceptional insight and a strategic mindset that strengthens our ability to help clients navigate highly complex HR and benefits projects,' said Kevin Overbey, President, Alliant Employee Benefits. 'She is a proven leader in developing solutions that drive both financial performance and employee well-being.' Lane has a longstanding track record of success across a range of industries, including healthcare, manufacturing, financial and business services, nonprofit, and faith-based organizations. Her expertise spans mergers and acquisitions due diligence, health trust management, alternative plan design, and financial modeling. She is highly regarded for her ability to align benefit strategies with broader organizational goals and deliver outcome-based solutions that support long-term success. Prior to joining Alliant, Lane served as Area Vice President with a global insurance brokerage and employee benefits consulting firm. Lane holds multiple professional certifications, including Licensed Group Benefits Associate (GBA) through the International Foundation of Employee Benefit Plans (IFEBP), Senior Certified Professional (SHRM-SCP) through the Society for Human Resource Management, and a Veterans at Work Certificate from SHRM. She attended Brigham Young University and Southern Maine University. About Alliant Insurance Services Alliant Insurance Services marks a century of success as the nation's leading specialty broker. We operate through a network of specialized national platforms and local offices to offer our clients a comprehensive portfolio of risk solutions built on innovative thinking and personal service. The business of managing risk is complex, and Alliant meets this complexity head-on with creativity and agility. Alliant has changed the way our clients approach risk management and benefits, giving them complete access to our resources and expertise—regardless of where the resource is located—to capitalize on new opportunities to grow and protect their organizations and their people. Alliant is recognized as a leading destination for top-tier brokerage talent in the U.S., attracting brokers and specialists across a diverse spectrum of disciplines who are eager to advance their careers. With the advantage of being majority employee-owned, professionals choose Alliant for autonomy, unparalleled resources, and a unique equity ownership opportunity. As a testament to our commitment to excellence, Alliant maintains an impressive 99% producer retention rate and has earned Forbes' prestigious title of one of America's Best Large Employers. Visit us at
